Quantity | = | Concentration | x | Volume | x | Molecular Weight |
---|---|---|---|---|---|---|
= | x | x |
1) Click the Molarity Calculation Cart® button.
2) Specify the Concentration and Volume of your desired Molarity.
3) Click Calculate.
4) Your desired Quantity will be calculated and will be put under Quantity: (only for mg)
5) Click Add to Cart and then Proceed to checkout to complete the order. You will receive the quantity as you ordered as solvent-free form.
Alert: If you want to make a solution with a solvent (such DMSO), please add instructions in the notes section (such as 10 nM/1 mL in DMSO) and we will pack and deliver the product as a solution (such as 10 nM solution in 1 mL DMSO). If the product cannot be dissolved in DMSO or you would like to specify your own preferred solvent, please add detailed instructions in the notes section. All solutions must be shipped with an ice bag, costing an additional fee of $20 for S&H.
NCTP05034
Description: Rabbit polyclonal to human PLK1
Application: ELISA, WB, IHC
Reactivity: Human
Catalog #: NCTP05034
$380
Warning: Last items in stock!
Availability date:
DESCRIPTION | |
Species Reactivity | Human. Predicted reacts with mouse, rat. Other species not tested. |
Isotype | IgG |
Immunogen | Recombinant human PLK1 protein 403-603aa |
Accession # | P53350 |
Alternative Names | Serine/threonine-protein kinase PLK1; PLK-1; STPK13; PLK |
Purification | Purified by protein A/G column. |
Formulation | Lyophilized with 0.02% NaN3. |
Size | 100µg/200µl |
APPLICATION | |
ELISA | 1:20,000-1:80,000 |
Western Blot | 1:500-1:1,000 |
Immunohistochemistry | 1:100-1:500 |
- | For research use only. Optimal dilutions/concentrations should be determined by each laboratory for each application. |
PREPARATION AND STORAGE | |
Reconstitution | Reconstitute in 200µl of sterile H2O. |
Storage | Shipped at ambient temperature. Store immediately at -20°C upon receipt. Avoid repeated freeze-thaw cycles. |
REFERENCES | |
- | Gleixner, K.V., Ferenc, V., Peter, B., et al. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res. 70 (4), 1513-1523 (2010). |